Brief: Gritstone Bio Announces Interim Results From Phase 1 SAMRNA COVID-19 Vaccine Study
08/06/2023 14:33
June 8 (Reuters) - Gritstone bio Inc GRTS.O :
* GRITSTONE BIO ANNOUNCES PUBLICATION OF INTERIM RESULTS
FROM
PHASE 1 STUDY OF SELF-AMPLIFYING MRNA (SAMRNA) VACCINE AGAINST
COVID-19 IN NATURE COMMUNICATIONS
* GRITSTONE BIO INC - POTENT AND DURABLE IMMUNOGENICITY
ACHIEVED
WITH LOW DOSE SELF-AMPLIFYING MRNA VACCINE (SAMRNA) CANDIDATE
Source text for Eikon: ID:nGNX1JqFk9
Further company coverage: GRTS.O
(Reuters.briefs@thomsonreuters.com)
Recent news on Gritstone bio
See all newsBrief: Gritstone Bio Inc On Dec 31 2024, Vassiliki “Celia” Economides Became Interim CEO As Well As CFO Of Co
Brief: Gritstone Bio Announces Strengthening Of Maturing Phase 2 PFS Data for GRANITE Study And Provides Business Update
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
U.S. STOCKS ON THE MOVE-PPG Industries, Travelers, ShiftPixy